Donzakimig 

Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G₄S)₂ linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions^[1].

Fab-G1-kappa-[scFv-heavy-kappa]2

Human

Fab-scFv/-scFv lacks an Fc domain structure: with one Fab fragment as the core, two single-chain variable fragments (scFv) with distinct specificities are fused to the C-termini of its two chains, respectively. The Fab and scFv are linked by an 11-amino acid flexible linker S (G₄S)₂, which ensures the spatial independence and antigen-binding activity of each binding domain^[1].
IL-13 is a core driver of allergic inflammation, airway hyperresponsiveness, and abnormal skin barrier function; IL-22 participates in epithelial cell activation, tissue remodeling, and inflammation amplification processes. The two exhibit synergistic pathogenic effects in diseases such as atopic dermatitis, asthma, and psoriasis, and dual-target blockade with Donzakimig can achieve stronger therapeutic efficacy^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3596  [NCBI] & 50616  [NCBI] & 213  [NCBI]

P35225 & Q9GZX6 & P02768

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

2765066-99-5

Liquid

Colorless to light yellow

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Fab-G1_kappa-scFv-heavy-kappa

• 
  Immobilized Human IL-22 Protein, His Tag can bind Donzakimig. The EC₅₀ for this effect is 232 ng/mL.
• 
  Immobilized Human ALB-His-Q Tag can bind Donzakimig. The EC₅₀ for this effect is 145.8 ng/mL.
• 
  Immobilized Human IL-13 Protein, His Tag can bind Donzakimig. The EC₅₀ for this effect is 287.2 ng/mL.

• [1]. Brinkmann U, et al. The making of multispecific immunoglobulins - a clinical perspective. MAbs. 2026;18(1):2613548.  [Content Brief]